Compare ESQ & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESQ | WVE |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.0M | 994.1M |
| IPO Year | 2017 | 2015 |
| Metric | ESQ | WVE |
|---|---|---|
| Price | $124.09 | $5.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | ★ $120.33 | $29.81 |
| AVG Volume (30 Days) | 128.6K | ★ 2.9M |
| Earning Date | 04-23-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | ★ 14.20 | N/A |
| EPS | ★ 2.89 | N/A |
| Revenue | N/A | ★ $3,704,000.00 |
| Revenue This Year | $35.15 | N/A |
| Revenue Next Year | $39.09 | $85.67 |
| P/E Ratio | $44.31 | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $92.33 | $5.01 |
| 52 Week High | $134.65 | $21.73 |
| Indicator | ESQ | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 51.97 | 39.41 |
| Support Level | $103.79 | N/A |
| Resistance Level | $134.03 | $6.39 |
| Average True Range (ATR) | 3.71 | 0.36 |
| MACD | -0.55 | -0.06 |
| Stochastic Oscillator | 12.76 | 16.07 |
Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.